extended follow-up from a trial of pembrolizumab plus axitinib for advanced renal cell carcinoma
Published 2 years ago • 60 plays • Length 3:26Download video MP4
Download video MP3
Similar videos
-
8:50
updated results of a clinical trial evaluating pembrolizumab axitinib for frontline adv rcc
-
4:17
longer term outcomes with pembrolizumab plus axitinib for advanced rcc
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
4:55
survival from ext follow-up of trial of nivolumab & ipilimumab for the 1st-line treatment of adv rcc
-
4:30
extended follow-up from trial of first-line pembrolizumab for patients w advanced urothelial cancer
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
2:23
overview of a phase iii trial of pembrolizumab plus axitinib in rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
10:06
lenvatinib and pembrolizumab compared to sunitinib for advanced renal cell carcinoma
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
9:52
phase 3 axitinib data in patients with previously treated advanced renal cell carcinoma
-
2:35
key data from asco gu 2019 on mrcc: pembrolizumab and axitinib as first-line therapy
-
1:06
exciting potential of pembrolizumab combined with axitinib for kidney cancer
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
4:30
neoadjuvant axitinib and avelumab for high-risk renal cell carcinoma
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:29
phase i/ii study of nivolumab and axitinib for advanced rcc